VRTX — Vertex Pharmaceuticals Incorporated stock price and chart

VRTX

Vertex Pharmaceuticals IncorporatedStock · HealthcareNasdaq-100 0.5% · Nasdaq Composite 0.2% · S&P 500 0.2% · Russell 1000 0.2% · Russell 3000 0.2% · US Stock Market 0.2% · S&P 500 Equal Weight 0.2% · MSCI World 0.1% · MSCI ACWI 0.1%

$515.44+0.17%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

100.0150.0200.0250.0300.0350.0400.0450.0500.0550.0020.0M$515.44

2026-09-11

Price$515.44

MA20$474.11

MA50$452.02

Vol5.3M

What would $1,000 invested in VRTX be worth today? →

VRTX returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $515.44
Change YTD: +13.69%
Next earnings: Nov 2, 2026
Market cap: 130.6B2016-09 21.6B2026-09 130.7B+504.2% over the window
Enterprise value: 124.8B
Shares outstanding: 253.5M2016-06 247.8M2026-06 253.5M+2.3% over the window
52W low: $374.17
52W high: $560.25
From 52W high: -8.00%
From 52W low: +37.76%
52W range: 76%
Beta: 0.30

Volume

Rel volume: 0.73×
30D volume: 1.1M
30D $ vol: 591.5M

Fundamentals

Sales (ttm): 12.6B2016-06 1.6B2026-06 12.6B+708.2% over the window
Sales/share: $49.662016-06 $6.292026-06 $49.66+690.1% over the window
EPS (ttm): $17.192016-06 -$1.132026-06 $17.19-1620.4% over the window
FCF (ttm): 3.8B2016-06 -56.4M2026-06 3.8B-6827.9% over the window
FCF/share: $14.982016-06 -$0.232026-06 $14.98-6677.1% over the window
Book value/share: $79.892016-06 $3.962026-06 $79.89+1917.0% over the window
Net margin: 35.00%2016-06 -17.7%2026-06 35.0%-298.2% over the window
ROE: 21.76%2016-06 -28.0%2026-06 21.8%-177.6% over the window
ROA: 16.06%2016-06 -10.8%2026-06 16.1%-248.9% over the window
Current ratio: 3.192016-06 2.332026-06 3.19+36.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +10.24%2025-06-30 → 2026-06-3011.4B → 12.6B (+10.2% total)+9.81%2023-06-30 → 2026-06-309.5B → 12.6B (+32.4% total)+13.50%2021-06-30 → 2026-06-306.7B → 12.6B (+88.3% total)+23.24%2016-06-30 → 2026-06-301.6B → 12.6B (+708.2% total)
Net income: +21.12%2025-06-30 → 2026-06-303.6B → 4.4B (+21.1% total)+9.39%2023-06-30 → 2026-06-303.4B → 4.4B (+30.9% total)+17.21%2021-06-30 → 2026-06-302B → 4.4B (+121.2% total)n/a
FCF: +8.48%2025-06-30 → 2026-06-303.5B → 3.8B (+8.5% total)-0.71%2023-06-30 → 2026-06-303.9B → 3.8B (-2.1% total)+16.39%2021-06-30 → 2026-06-301.8B → 3.8B (+113.6% total)n/a
Shares: -1.14%2025-06-30 → 2026-06-30256.4M → 253.5M (-1.1% total)-0.60%2023-06-30 → 2026-06-30258.1M → 253.5M (-1.8% total)-0.46%2021-06-30 → 2026-06-30259.4M → 253.5M (-2.3% total)+0.23%2016-06-30 → 2026-06-30247.8M → 253.5M (+2.3% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +22.47%2025-06-30 → 2026-06-30$14.04 → $17.19 (+22.4% total)+9.93%2023-06-30 → 2026-06-30$12.94 → $17.19 (+32.9% total)+17.79%2021-06-30 → 2026-06-30$7.58 → $17.19 (+126.7% total)n/a
Sales/share: +11.51%2025-06-30 → 2026-06-30$44.54 → $49.66 (+11.5% total)+10.48%2023-06-30 → 2026-06-30$36.83 → $49.66 (+34.8% total)+14.03%2021-06-30 → 2026-06-30$25.76 → $49.66 (+92.8% total)+22.96%2016-06-30 → 2026-06-30$6.29 → $49.66 (+690.1% total)
FCF/share: +9.73%2025-06-30 → 2026-06-30$13.65 → $14.98 (+9.7% total)-0.11%2023-06-30 → 2026-06-30$15.03 → $14.98 (-0.3% total)+16.94%2021-06-30 → 2026-06-30$6.85 → $14.98 (+118.6% total)n/a
Book value/share: +19.27%2025-06-30 → 2026-06-30$66.99 → $79.89 (+19.3% total)+10.05%2023-06-30 → 2026-06-30$59.94 → $79.89 (+33.3% total)+17.65%2021-06-30 → 2026-06-30$35.45 → $79.89 (+125.4% total)+35.05%2016-06-30 → 2026-06-30$3.96 → $79.89 (+1917.0% total)
Price: +29.74%2025-09-11 → 2026-09-11$397.37 → $515.44 (+29.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+14.07%2023-09-11 → 2026-09-11$347.22 → $515.44 (+48.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+22.27%2021-09-10 → 2026-09-11$188.57 → $515.44 (+173.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+18.58%2016-09-09 → 2026-09-11$93.68 → $515.44 (+450.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +29.74%2025-09-11 → 2026-09-11$397.37 → $515.44 (+29.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.07%2023-09-11 → 2026-09-11$347.22 → $515.44 (+48.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+22.27%2021-09-10 → 2026-09-11$188.57 → $515.44 (+173.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+18.58%2016-09-09 → 2026-09-11$93.68 → $515.44 (+450.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 30.0×2016-09 -98.892026-09 29.67-130.0% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 27.4×2016-09 -259.342026-09 27.36-110.5% over the window
Fwd P/E: 26.1×
P/S (ttm)Market cap ÷ TTM revenue.: 10.4×2016-09 13.022026-09 10.38-20.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.5×2016-09 21.172026-09 6.45-69.5% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 34.4×2016-09 326.652026-09 34.43-89.5% over the window
EV/EBITDA (fy): 25.0×
EV/Sales (ttm): 9.9×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.91%2016-06 -0.3%2026-06 3.0%-1249.6% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 253.5M ÷ 256.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.14%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.14%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($114.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 1.14%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($2B) ÷ today's market cap ($130.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.54%2016-06 0.0%2026-06 1.6%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $2B + TTM dividends $0) ÷ today's market cap ($130.6B). Same caveat as the cash buyback yield.: 1.54%2016-06 0.0%2026-06 1.6%

Vs own 10Y history

P/E: 61st
P/OI: 48th
P/S: 45th
P/B: 41st
P/FCF: 58th

Bar = where today’s multiple sits in VRTX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

+0.17%

-7.62%

-1.96%

+15.82%

YTD

+13.69%

+32.66%

+158.73%

Financial statements

Open full VRTX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Vertex Pharmaceuticals Incorporated (VRTX) trades at $515.44 with a live price and an interactive chart covering 35+ years of daily price history, plus key valuation metrics. ChartRow also publishes VRTX’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full VRTX financial statements →

VRTX — Vertex Pharmaceuticals Incorporated price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · windows as of 2026-09-11

Financial statements

Related Healthcare